Juan Valle

List of Publications by Year
in descending order

310 papers	29,116 citations	15466 65 h-index	5663 162 g-index
316 all docs	316 docs citations	316 times ranked	21270 citing authors

#	Article	IF	Citations
1	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	1.2	13
2	Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study. Neuroendocrinology, 2022, 112, 298-310.	1.2	6
3	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. Neuroendocrinology, 2022, 112, 88-100.	1.2	6
4	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. British Journal of Cancer, 2022, 126, 693-705.	2.9	18
5	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	3.2	20
6	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open, 2022, 7, 100377.	2.0	8
7	A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.. Journal of Clinical Oncology, 2022, 40, 378-378.	0.8	146
8	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. Oncologist, 2022, 27, 97-103.	1.9	6
9	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	1.8	119
10	Perspective on Immunotherapy Use in Biliary Tract Cancer. , 2022, , 207-218.		0
11	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. Cancers, 2022, 14, 1017.	1.7	2
12	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	0.5	3
13	Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 1789.	1.7	7
14	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology, 2022, 40, 2048-2057.	0.8	65
15	ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer groupâ€™s perspective. ESMO Open, 2022, 7, 100392.	2.0	1
16	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open, 2022, 7, 100417.	2.0	3
17	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. Clinical Colorectal Cancer, 2022, , .	1.0	0
18	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. British Journal of Cancer, 2022, 127, 531-540.	2.9	11

#	Article	IF	Citations
19	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of Surgical Oncology, 2022, 29, 5568-5577.	0.7	4
20	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	6.1	11
21	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. , 2022, 1, .		267
22	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Review of Anticancer Therapy, 2022, 22, 1009-1015.	1.1	2
23	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology, 2021, 73, 2311-2325.	3.6	40
24	Liver Embolisation for Patients with Neuroendocrine Neoplasms: Systematic Review. Neuroendocrinology, 2021, 111, 354-369.	1.2	17
25	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. European Journal of Surgical Oncology, 2021, 47, 583-590.	0.5	7
26	Outcomes in older patients with biliary tract cancer. European Journal of Surgical Oncology, 2021, 47, 569-575.	0.5	5
27	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). Oncologist, 2021, 26, e669-e678.	1.9	15
28	Reply to Comment on â€œThe UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemicâ€• British Journal of Cancer, 2021, 124, 679-680.	2.9	0
29	Biliary tract cancer. Lancet, The, 2021, 397, 428-444.	6.3	429
30	Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.. Journal of Clinical Oncology, 2021, 39, 266-266.	0.8	41
31	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	1.3	12
32	In Reply. Oncologist, 2021, 26, e903-e904.	1.9	0
33	HPB cancers in older patients | inclusion of older/senior patients in clinical trials. European Journal of Surgical Oncology, 2021, 47, 597-602.	0.5	4
34	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	3.4	6
35	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 301-307.	1.9	5
36	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANTâ€3 and RADIANTâ€4 trials. Cancer, 2021, 127, 2674-2682.	2.0	4

#	Article	IF	Citations
37	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2021, 22, 690-701.	5.1	396
38	Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine		

#	Article	IF	Citations
55	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer. Pancreas, 2021, 50, 1254-1259.	0.5	4
56	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	1.7	5
57	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nature Communications, 2021, 12, 7336.	5.8	40
58	Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials. Journal of the National Cancer Institute, 2020, 112, 200-210.	3.0	90
59	Temozolomide-Capecitabine Chemotherapy for Neuroendocrine Neoplasms: The Dilemma of Treatment Duration. Neuroendocrinology, 2020, 110, 155-157.	1.2	8
60	Identification of Areas for Improvement in the Management of Bone Metastases in Patients with Neuroendocrine Neoplasms. Neuroendocrinology, 2020, 110, 688-696.	1.2	6
61	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treatment Reviews, 2020, 84, 101936.	3.4	73
62	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study. BMJ Open, 2020, 10, e027630.	0.8	6
63	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	2.9	37
64	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma withFGFR2rearrangements. Future Oncology, 2020, 16, 2385-2399.	1.1	96
65	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers, 2020, 12, 1988.	1.7	12
66	Fibrolamellar carcinoma: Challenging the challenge. European Journal of Cancer, 2020, 137, 144-147.	1.3	5
67	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews, 2020, 89, 102084.	3.4	61
68	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology, 2020, 20, 1682-1688.	0.5	13
69	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. Journal of Clinical Medicine, 2020, 9, 2854.	1.0	61
70	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. Cancers, 2020, 12, 2375.	1.7	2
71	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. ESMO Open, 2020, 5, e000633.	2.0	1
72	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. Pancreatology, 2020, 20, 668-675.	0.5	12

#	Article	IF	Citations
73	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 2020, 10, e034527.	0.8	11
74	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	5.1	620
75	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical Oncology, 2020, 37, 61.	1.2	9
76	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 364-369.	1.1	7
77	Reaching out beyond first-line treatments in advanced biliary tract cancers. Annals of Oncology, 2020, 31, 1099-1102.	0.6	1
78	Molecular targeted therapies: Ready for â€œprime timeâ€•in biliary tractÂcancer. Journal of Hepatology, 2020, 73, 170-185.	1.8	226
79	Pancreatic cancer. Lancet, The, 2020, 395, 2008-2020.	6.3	1,376
80	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	8.2	1,155
81	The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology. ESMO Open, 2020, 5, e000709.	2.0	11
82	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 2020, 123, 709-713.	2.9	20
83	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. Journal of Vascular and Interventional Radiology, 2020, 31, 1035-1043.e2.	0.2	49
84	The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Pancreas, 2020, 49, 201-207.	0.5	6
85	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. British Journal of Cancer, 2020, 122, 971-977.	2.9	30
86	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 398-411.	5.1	152
87	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 1760-1768.	2.9	14
88	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology, 2020, 73, 1109-1117.	1.8	25
89	Ramucirumab (RAM) or merestinib (MER) or placebo (PL) plus gemcitabine (GEM) and cisplatin (CIS) as first-line treatment for advanced or metastatic biliary tract cancer (BTC): A randomized, double-blind, phase II study.. Journal of Clinical Oncology, 2020, 38, 477-477.	0.8	26
90	A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).. Journal of Clinical Oncology, 2020, 38, TPS600-TPS600.	0.8	34

#	Article	IF	Citations
91	Clinical and Translational Research Challenges in Biliary Tract Cancers. Current Medicinal Chemistry, 2020, 27, 4756-4777.	1.2	21
92	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081.	1.1	15
93	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	0.8	49
94	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	1.6	36
95	Targeted therapy for cholangiocarcinoma. The Lancet Gastroenterology and Hepatology, 2019, 4, 661-662.	3.7	3
96	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes . Cancer Management and Research, 2019, Volume 11, 7537-7556.	0.9	3
97	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. Journal of Clinical Medicine, 2019, 8, 1630.	1.0	10
98	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013â€“2015. British Journal of Cancer, 2019, 121, 966-972.	2.9	44
99	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 1038.	2.2	154
100	Outcomes in patientsâ€‰â‰¥â€‰80Âyears with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Medical Oncology, 2019, 36, 85.	1.2	6
101	Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas. Neuroendocrinology, 2019, 109, 100-112.	1.2	27
102	Observational Study to Assess Quality of Life in Patients with Pancreatic Neuroendocrine Tumors Receiving Treatment with Everolimus: The OBLIQUE Study (UK Phase IV Trial). Neuroendocrinology, 2019, 108, 317-327.	1.2	16
103	Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology, 2019, 15, 1219-1230.	1.1	17
104	Biliary tract cancers: current knowledge, clinical candidates and future challenges . Cancer Management and Research, 2019, Volume 11, 2623-2642.	0.9	78
105	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, The, 2019, 20, 663-673.	5.1	773
106	Medical treatment for cholangiocarcinoma. Liver International, 2019, 39, 123-142.	1.9	69
107	Adjuvant chemotherapy and outcomes in patients with nodal and resection marginâ€negative pancreatic ductal adenocarcinoma: A systematic review and metaâ€analysis. Journal of Surgical Oncology, 2019, 119, 932-940.	0.8	11
108	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	0.8	301

#	Article	IF	Citations
109	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 115-129.	1.8	76
110	Colorectal Neuroendocrine Neoplasms: Areas of Unmet Need. Neuroendocrinology, 2019, 108, 45-53.	1.2	22
111	Novel Treatments for Advanced Cholangiocarcinoma. , 2019, , 227-243.		0
112	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	0.5	34
113	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clinical and Translational Oncology, 2019, 21, 950-953.	1.2	9
114	Unmet Medical Needs in Pulmonary Neuroendocrine (Carcinoid) Neoplasms. Neuroendocrinology, 2019, 108, 7-17.	1.2	19
115	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	2.1	189
116	ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.. Journal of Clinical Oncology, 2019, 37, 4003-4003.	0.8	166
117	Final results of the TALENT trial (GETNE1509): a prospective multicohort phase II study of lenvatinib in patients (pts) with G1/G2 advanced pancreatic (panNETs) and gastrointestinal (giNETs) neuroendocrine tumors (NETs).. Journal of Clinical Oncology, 2019, 37, 4106-4106.	0.8	25
118	Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.. Journal of Clinical Oncology, 2019, 37, TPS4155-TPS4155.	0.8	20
119	FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.. Journal of Clinical Oncology, 2019, 37, TPS468-TPS468.	0.8	6
120	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	0.4	13
121	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 43-43.	0.4	16
122	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954.	2.9	30
123	Biliary Tract Cancer: Implicated Immune-Mediated Pathways and Their Associated Potential Targets. Oncology Research and Treatment, 2018, 41, 298-304.	0.8	8
124	Circulating Tumor Cells. , 2018, , 1325-1360.		1
125	Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088.	2.9	9
126	68Gallium DOTANOC-PET Imaging in Lung Carcinoids: Impact on Patients' Management. Neuroendocrinology, 2018, 106, 128-138.	1.2	15

#	Article	IF	Citations
127	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology, 2018, 106, 211-220.	1.2	35
128	A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7	1.1	21
129	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. British Journal of Cancer, 2018, 118, 181-188.	2.9	23
130	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nature Communications, 2018, 9, 4672.	5.8	47
131	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinomaâ€"a meta-analysis. European Journal of Cancer, 2018, 105, 1-9.	1.3	69
132	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE, 2018, 13, e0206007.	1.1	14
133	Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2018, 7, 947-958.	0.6	5
134	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews, 2018, 70, 168-177.	3.4	55
135	Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical Therapeutics, 2018, 40, 952-962.e2.	1.1	19
136	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 2018, 119, 27-35.	2.9	19
137	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	1.7	21
138	Irreversible Electroporation in pancreatic ductal adenocarcinoma: IsÂthere a role in conjunction with conventional treatment?. European Journal of Surgical Oncology, 2018, 44, 1486-1493.	0.5	11
139	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Review of Gastroenterology and Hepatology, 2018, 12, 723-731.	1.4	37
140	PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer. ESMO Open, 2018, 3, e000379.	2.0	20
141	PRIMUS-001: An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation (ISRCTN75002153) â€" Part of Precision-Panc.. Journal of Clinical Oncology, 2018, 36, TPS4158-TPS4158.	0.8	5
142	ACELARATE: A phase III, open label, multicentre randomised clinical study comparing Acelarin (NUC-1031) with gemcitabine in patients with metastatic pancreatic carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS537-TPS537.	0.8	3
143	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget, 2018, 9, 14922-14938.	0.8	29
144	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. Cancer, 2017, 123, 888-890.	2.0	2

#	Article	IF	Citations
145	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	6.3	1,475
146	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	5.1	60
147	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. Human Pathology, 2017, 66, 239-240.	1.1	0
148	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	0.6	82
149	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy. Neuroendocrinology, 2017, 105, 281-294.	1.2	94
150	Current Status on Cholangiocarcinoma and Gallbladder Cancer. Liver Cancer, 2017, 6, 59-65.	4.2	73
151	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological, Nuclear Medicine and Hybrid Imaging. Neuroendocrinology, 2017, 105, 212-244.	1.2	325
152	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	1.2	122
153	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews, 2017, 36, 141-157.	2.7	119
154	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1411-1422.	5.1	74
155	New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open, 2017, 2, e000152.	2.0	26
156	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. Journal of the National Cancer Institute, 2017, 109, djw277.	3.0	28
157	New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discovery, 2017, 7, 943-962.	7.7	419
158	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. BMC Cancer, 2017, 17, 262.	1.1	16
159	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Current Oncology Reports, 2017, 19, 50.	1.8	17
160	The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy, 2017, 66, 1425-1436.	2.0	271
161	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of Oncology, 2017, 28, 339-343.	0.6	144
162	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. Clinical and Translational Oncology, 2017, 19, 579-586.	1.2	32

#	Article	IF	Citations
163	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	1.8	21
164	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. OncoTargets and Therapy, 2017, Volume 10, 5013-5030.	1.0	8
165	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology, 2017, 35, 14-23.	0.8	258
166	Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.. Journal of Clinical Oncology, 2017, 35, 4006-4006.	0.8	142
167	A randomized phase II trial comparing different schedules of nab-paclitaxel (nabP) combined with gemcitabine (GEM) as first line treatment for metastatic pancreatic adenocarcinoma (PDAC).. Journal of Clinical Oncology, 2017, 35, 342-342.	0.8	1
168	Gemcitabine and cisplatin plus ramucirumab or merestinib or placebo in first-line treatment for advanced or metastatic biliary tract cancer: A double-blind, randomized phase II trial.. Journal of Clinical Oncology, 2017, 35, TPS509-TPS509.	0.8	5
169	Circulating Tumour Cells. , 2017, , 1-36.		0
170	Consensus treatment guidelines for urgent symptoms in cholangiocarcinoma (CC) patients (pts) with biliary stents or catheters using the modified RAND/UCLA Delphi process.. Journal of Clinical Oncology, 2017, 35, 452-452.	0.8	0
171	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	0.6	17
172	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	1.4	25
173	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted Oncology, 2016, 11, 815-824.	1.7	45
174	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. Surgical Oncology, 2016, 25, 223-228.	0.8	13
175	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British Journal of Cancer, 2016, 114, 965-971.	2.9	39
176	Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer, 2016, 115, 1032-1038.	2.9	25
177	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 2016, 115, 420-424.	2.9	9
178	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v28-v37.	0.6	523
179	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 563-570.	1.6	24
180	Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology, 2016, 12, 2561-2578.	1.1	3

#	Article	IF	Citations
181	Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2487-2498.	0.9	27
182	Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Annals of Clinical Biochemistry, 2016, 53, 554-560.	0.8	59
183	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153.	1.1	62
184	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. Cancer Treatment Reviews, 2016, 44, 26-41.	3.4	45
185	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease, 2016, 48, 552-558.	0.4	44
186	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2016, 387, 968-977.	6.3	962
187	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	2.0	10
188	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	0.6	88
189	Everolimus (EVE) in advanced, nonfunctional, well-differentiated neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin: Second interim overall survival (OS) results from the RADIANT-4 study.. Journal of Clinical Oncology, 2016, 34, 4090-4090.	0.8	8
190	ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology, 2016, 34, LBA4006-LBA4006.	0.8	5
191	Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.. Journal of Clinical Oncology, 2016, 34, 309-309.	0.8	5
192	Efficacy and safety of everolimus in advanced, progressive, nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract and unknown primary: A subgroup analysis of the phase III RADIANT-4 trial.. Journal of Clinical Oncology, 2016, 34, 315-315.	0.8	7
193	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. Cancer Research Frontiers, 2016, 2, 352-367.	0.2	10
194	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World Journal of Gastroenterology, 2016, 22, 6065.	1.4	23
195	Systemic therapy in elderly patients with advanced biliary tract cancer: Sub-analysis of ABC-02 and 10 other prospective studies.. Journal of Clinical Oncology, 2016, 34, 382-382.	0.8	0
196	Prognostic influence of clinical biomarkers in patients (pts) with advanced hepatocellular carcinoma (HCC) receiving sorafenib: A single institution experience.. Journal of Clinical Oncology, 2016, 34, 304-304.	0.8	0
197	REMINET: A European, multicentre, PHASE II/III randomized double-blind, placebo-controlled study evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.. Journal of Clinical Oncology, 2016, 34, TPS4148-TPS4148.	0.8	0
198	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Journal of Gastrointestinal Cancer, 2015, 46, 201-211.	0.6	199

#	Article	IF	Citations
199	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
200	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer, 2015, 51, 1381-1388.	1.3	19
201	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European Journal of Cancer, 2015, 51, 1694-1703.	1.3	25
202	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 967-978.	5.1	221
203	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. Journal of Clinical Oncology, 2015, 33, 2405-2406.	0.8	7
204	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 1099-1114.	1.1	13
205	The role of adjuvant chemotherapy andÂradiotherapy for cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 333-343.	1.0	32
206	Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1511-1519.	1.8	99
207	Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. Clinical Oncology, 2015, 27, 741-746.	0.6	17
208	A prospective, single-arm, phase I/II trial of RAS peptide vaccine TG01/GM-CSF and gemcitabine as adjuvant therapy for patients with resected pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 4121-4121.	0.8	5
209	Baseline demographics of the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, 276-276.	0.8	2
210	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. Journal of Clinical Oncology, 2015, 33, 3545-3545.	0.8	0
211	Baseline demographics of patients from the randomized, placebo-controlled, double-blind, phase III RADIANT-4 study of everolimus in nonfunctional gastrointestinal (GI) or lung neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, e15197-e15197.	0.8	0
212	Prognostic score in high-grade gastrointestinal neuroendocrine tumours (GI-NETs).. Journal of Clinical Oncology, 2015, 33, 4089-4089.	0.8	0
213	Pancreatic Malignancy and Nutrition: a Study of Clinical Practice.. Annals of Oncology, 2014, 25, iv535.	0.6	0
214	Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. British Journal of Cancer, 2014, 111, 1703-1709.	2.9	41
215	Determination of the Optimal Echocardiographic Scoring System to Quantify Carcinoid Heart Disease. Neuroendocrinology, 2014, 99, 85-93.	1.2	29
216	Second-line chemotherapy in advanced biliary cancer: a systematic review. Annals of Oncology, 2014, 25, 2328-2338.	0.6	279

#	Article	IF	Citations
217	Reply to the letter to the editor â€˜Second-line chemotherapy in advanced biliary cancer: the present now will later be pastâ€™ by Vivaldi et al.. Annals of Oncology, 2014, 25, 2444-2445.	0.6	1
218	Combination therapy of 177Lu and 90Y Dotatate for treatment of neuroendocrine cancer. Nuclear Medicine Communications, 2014, 35, 585-587.	0.5	0
219	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2014, 40, 1230-1238.	3.4	34
220	Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocrine-Related Cancer, 2014, 21, R485-R493.	1.6	22
221	Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. Journal of Clinical Gastroenterology, 2014, 48, 430-434.	1.1	24
222	Capecitabine and streptozocinÂ±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, 2014, 50, 902-911.	1.3	56
223	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Translational Oncology, 2014, 7, 55-64.	1.7	16
224	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treatment Reviews, 2014, 40, 376-389.	3.4	46
225	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 2014, 106, djt347.	3.0	231
226	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 2014, 63, 175-183.	2.0	80
227	A comparison of diagnostic imaging modalities for colorectal liver metastases. European Journal of Surgical Oncology, 2014, 40, 545-550.	0.5	34
228	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of Clinical Oncology, 2014, 32, 504-512.	0.8	351
229	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	5.1	296
230	Erratum to â€œA systematic review of non-surgical treatments for pancreatic neuroendocrine tumoursâ€• [Cancer Treat Rev 40 (2014) 376â€“389]. Cancer Treatment Reviews, 2014, 40, 1037.	3.4	3
231	Circulating biomarkers in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 323-332.	1.1	56
232	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of Oncology, 2014, 25, 391-398.	0.6	314
233	Methods for Adjusting for Bias Due to Crossover in Oncology Trials. Pharmacoeconomics, 2014, 32, 533-546.	1.7	42
234	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncology, The, 2014, 15, 601-611.	5.1	371

#	Article	IF	Citations
235	BINGO: targeted therapy for advanced biliary-tract cancer. Lancet Oncology, The, 2014, 15, 778-780.	5.1	4
236	Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.. Journal of Clinical Oncology, 2014, 32, 3556-3556.	0.8	3
237	Analysis of progression-free survival in the new EPOC study in an â€œall wild-typeâ€•population.. Journal of Clinical Oncology, 2014, 32, 3566-3566.	0.8	1
238	Patient-reported satisfaction with symptom control during lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients: Symnet, a large multinational, cross-sectional, observational study.. Journal of Clinical Oncology, 2014, 32, 273-273.	0.8	5
239	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. The Journal of Oncopathology, 2014, 2, 15-25.	0.1	2
240	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. The Journal of Oncopathology, 2014, 2, 57-68.	0.1	3
241	Clinical Management of Targeted Therapies in Neuroendocrine Tumours. , 2014, , 141-154.		0
242	Efficacy and safety of cisplatin and gemcitabine (CG) chemotherapy for advanced biliary tract cancer (ABC) in jaundiced patients (pts).. Journal of Clinical Oncology, 2014, 32, 294-294.	0.8	0
243	Proportional shortfall due to pancreatic cancer in Europe: Survival and quality of life analysis based on a systematic review.. Journal of Clinical Oncology, 2014, 32, e15253-e15253.	0.8	0
244	Lanreotide autogel/depot (LAN) treatment for carcinoid syndrome (CS) symptoms: Patient-reported outcomes (PROs) from the SYMNET study.. Journal of Clinical Oncology, 2014, 32, 4111-4111.	0.8	0
245	Outcome of second-line chemotherapy for biliary tract cancer. European Journal of Cancer, 2013, 49, 1511.	1.3	45
246	A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.. Journal of Clinical Oncology, 2013, 31, 3504-3504.	0.8	34
247	HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.. Journal of Clinical Oncology, 2013, 31, 4006-4006.	0.8	15
248	Pilot, proof-of-concept studies for determining the feasibility of the use of FLT-PET in patients with pancreatic adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, TPS4146-TPS4146.	0.8	2
249	A phase III randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer.. Journal of Clinical Oncology, 2013, 31, LBA4004-LBA4004.	0.8	13
250	The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study. PLoS ONE, 2013, 8, e73679.	1.1	53
251	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 2012, 106, 508-516.	2.9	233
252	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma. JAMA - Journal of the American Medical Association, 2012, 308, 147.	3.8	499

#	Article	IF	Citations
253	Updated results from a phase III trial of sunitinib versus placebo in patients with progressive, unresectable, well-differentiated pancreatic neuroendocrine tumor (NET).. Journal of Clinical Oncology, 2012, 30, 4118-4118.	0.8	11
254	Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial.. Journal of Clinical Oncology, 2012, 30, 4121-4121.	0.8	3
255	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513.	13.9	2,216
256	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 31-39.	2.0	33
257	Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1817-1827.	1.1	7
258	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational New Drugs, 2011, 29, 1029-1037.	1.2	269
259	Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. Cancer Chemotherapy and Pharmacology, 2011, 67, 1111-1117.	1.1	14
260	Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2004-2010.	0.8	150
261	A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Annals of Oncology, 2011, 22, 2042-2048.	0.6	197
262	Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo.. Journal of Clinical Oncology, 2011, 29, 249-249.	0.8	2
263	Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer. Clinical Oncology, 2010, 22, 570-577.	0.6	15
264	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British Journal of Cancer, 2010, 103, 315-323.	2.9	9
265	Reply: Guesstimates are not good enough for determining what is happening in routine care. British Journal of Cancer, 2010, 103, 1887-1888.	2.9	0
266	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. JAMA - Journal of the American Medical Association, 2010, 304, 1073.	3.8	1,206
267	Advances in the treatment of metastatic or unresectable biliary tract cancer. Annals of Oncology, 2010, 21, vii345-vii348.	0.6	74
268	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer, 2010, 46, 526-533.	1.3	30
269	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 2010, 362, 1273-1281.	13.9	3,370
270	Patient-reported outcomes (PROs) in patients (pts) with pancreatic neuroendocrine tumors (NET) receiving sunitinib (SU) in a phase III trial.. Journal of Clinical Oncology, 2010, 28, 4003-4003.	0.8	5

#	Article	IF	Citations
271	Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2010, 28, e13580-e13580.	0.8	5
272	ABC-03: A randomized, phase II/III study of cediranib (AZD2171) or placebo in combination with cisplatin/gemcitabine for patients with advanced biliary tract cancers.. Journal of Clinical Oncology, 2010, 28, TPS218-TPS218.	0.8	2
273	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	0.8	708
274	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study â€“ The UK ABC-01 Study. British Journal of Cancer, 2009, 101, 621-627.	2.9	243
275	UGT1A1*28genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. Pharmacogenomics, 2009, 10, 733-739.	0.6	34
276	Pneumoperitoneum Following Percutaneous Biliary Intervention: Not Necessarily a Cause for Alarm. CardioVascular and Interventional Radiology, 2008, 31, 439-443.	0.9	3
277	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 579-585.	1.1	17
278	A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Supportive Care in Cancer, 2008, 16, 201-208.	1.0	100
279	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer, 2008, 99, 577-583.	2.9	7
280	A Phase I Study of the Safety and Pharmacokinetics of the Combination of Pertuzumab (rhuMab 2C4) and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2008, 14, 2726-2731.	3.2	43
281	A phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine. Journal of Clinical Oncology, 2008, 26, 4636-4636.	0.8	5
282	Capecitabine (X) following short-course capecitabine + oxaliplatin (XELOX) in advanced colorectal cancer (CRC): Phase II XelQuali study. Journal of Clinical Oncology, 2008, 26, 15042-15042.	0.8	0
283	Efficacy and toxicity of limited field concurrent chemoradiotherapy (CRT) with capecitabine for locally advanced pancreatic cancer (LAPC). Journal of Clinical Oncology, 2008, 26, 15586-15586.	0.8	0
284	Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study. British Journal of Cancer, 2007, 96, 38-43.	2.9	12
285	Phase I Evaluation of a Fully Human Antiâ€“Î±v Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 2128-2135.	3.2	136
286	Phase I Evaluation of CDP791, a PEGylated Di-Fabâ€² Conjugate that Binds Vascular Endothelial Growth Factor Receptor 2. Clinical Cancer Research, 2007, 13, 7113-7118.	3.2	69
287	Patients With Pancreatic Cancer Participating in Clinical Trials. Pancreas, 2007, 34, 269-270.	0.5	1
288	Cytotoxic chemotherapy for advanced, non-resectable colorectal cancer. European Journal of Surgical Oncology, 2007, 33, S17-S23.	0.5	0

#	Article	IF	Citations
289	Metastatic Colorectal Cancer. Drugs, 2007, 67, 1851-1867.	4.9	36
290	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (LV) (SCOUT) in patients with advanced colorectal cancer (ACRC): A phase I/II study. Journal of Clinical Oncology, 2007, 25, 4084-4084.	0.8	4
291	A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?. Pancreas, 2006, 32, 51-57.	0.5	12
292	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. British Journal of Cancer, 2006, 95, 450-456.	2.9	10
293	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. Journal of Cancer Research and Clinical Oncology, 2006, 132, 41-44.	1.2	9
294	Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial. Clinical Cancer Research, 2006, 12, 3416-3424.	3.2	148
295	Irinotecan with Bolus and Infusional 5-flurouracil and Folinic Acid for Patients with Advanced or Metastatic Colorectal Cancer Previously Treated with 5-flurouracil: A Possible Alternative to Single-agent Irinotecan in a â€˜Real-lifeâ€™ Setting. Clinical Oncology, 2005, 17, 666.	0.6	0
296	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. Journal of Clinical Oncology, 2005, 23, 973-981.	0.8	167
297	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. British Journal of Cancer, 2005, 92, 628-630.	2.9	22
298	Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. British Journal of Cancer, 2004, 91, 1447-1452.	2.9	4
299	Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer. British Journal of Cancer, 2003, 88, 1153-1154.	2.9	0
300	961 Phase I study of escalating doses of TroVaxÂ® in patients wtih advanced colorectal cancer (CRC). European Journal of Cancer, Supplement, 2003, 1, S289.	2.2	0
301	Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer. Journal of Clinical Oncology, 2002, 20, 1996-2004.	0.8	449
302	Why hasn't the National Institute been â€˜NICEâ€™ to patients with colorectal cancer?. British Journal of Cancer, 2002, 86, 1667-1669.	2.9	7
303	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer, 2001, 92, 601-608.	2.0	49
304	Adjuvant therapy for gastric cancer â€“ has the standard changed?. British Journal of Cancer, 2001, 84, 875-877.	2.9	4
305	Pharmacokinetics of a hematoregulatory peptide (SK&F107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy. Pharmaceutical Research, 2000, 17, 385-390.	1.7	2
306	Letters to the editor. Annals of Oncology, 1997, 8, 405.	0.6	7

#	Article	IF	Citations
307	Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. European Journal of Cancer, 1997, 33, 2183-2193.	1.3	54
308	Review of recent trials of chemotherapy for advanced breast cancer: Studies excluding taxanes. European Journal of Cancer, 1997, 33, 2171-2182.	1.3	11
309	i and fatal neutropen and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clinical Oncology, 1997, 9, 172-175.	0.6	6
310	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1